(Finance) – Shine Sonoma Pharmaceuticals,which changes hands with an increase of 32.89%.
The pharmaceutical company has launched a new surgical application for its intraoperative pulse lavage irrigation treatment. The treatment will be available in Europe as early as this year, while it will be sold in the United States starting in 2024.
The comparison of the title with the NASDAQ 100on a weekly basis, shows the greatest relative strength of Sonoma Pharmaceuticals, compared to the index, highlighting the concrete attractiveness of the stock by buyers.
Technically, the medium-term situation is negative, while bullish signs can be glimpsed in the short term, thanks to the stability of the support area identified at USD 1.199. The positive momentum in the short term is indicative of a change in trend towards a bullish scenario, with the curve that could push towards the important resistance area estimated at 1.449 level. At an operational level, the most appropriate scenario could be a bullish recovery of the stock, with a resistance area identified at 1.699.